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A two-step fluorinase enzyme mediated 18F labelling
of an RGD peptide for positron emission
tomography†
S. Thompson,a M. Onega,b S. Ashworth,b I. N. Fleming,c J. Passchierb and
D. O’Hagan*a
A two-step radiolabelling protocol of a cancer relevant cRGD peptide
is described where the fluorinase enzyme is used to catalyse a
transhalogenation reaction to generate [18F]-50-fluoro-50-deoxy-2-
ethynyladenosine, [18F]FDEA, followed by a ‘click’ reaction to an
azide tethered cRGD peptide. This protocol oﬀers eﬃcient radio-
labelling of a biologically relevant peptide construct in water at
pH 7.8, 37 8C in 2 hours, which was metabolically stable in rats and
retained high aﬃnity for aVb3 integrin.
The fluorinase enzyme,1 involved in the first step of fluoro-
metabolite biosynthesis in a select few bacteria,2,3 catalyses the
reaction of S-adenosyl-L-methionine (SAM, 1) and the fluoride ion
to generate 50-fluoro-50-deoxyadenosine (FDA, 2) and L-methionine
(L-Met, 3) (Scheme 1A). The enzyme will also catalyse a transhalo-
genation reaction when 50-chloro-50-deoxyadenosine (ClDA, 4) is
presented as a substrate with L-selenomethionine (SeMet) and
fluoride.4 In this case a reverse reaction occurs where SeMet
attacks ClDA 4 and generates selenoSAM (SeSAM, 5) in situ, after
which the fluoride ion, the favoured nucleophile, reacts with
SeSAM 5 to generate FDA 2 (Scheme 1B).
Positron emission tomography (PET) has emerged as indispen-
sable functional imaging modality, complementary to anatomical
imaging modalities such as magnetic resonance imaging (MRI)
and computerised tomography (CT).5 The development of new
methodologies for labelling molecules with positron emitting iso-
topes (such as carbon-11 and fluorine-18) continues to receive
widespread attention, especially for labelling biomolecules.6
[18F]Fluoride is generated on a cyclotron from [18O]water, and thus
in an aqueous form. Themost widespread approach for fluorine-18
labelling of biomolecules involves the synthesis of a [18F]-bearing
prosthetic group by conventional nucleophilic substitution
chemistry using [18F]fluoride, which has been azeotropically
dried from [18O]water and formulated in a dry, polar aprotic
solvent as the potassium-kryptofix-222 salt.7 Commonly used
prosthetic groups include N-succinimydyl 4-[18F]fluorobenzoate
([18F]SFB)8 and 4-[18F]fluorobenzaldehyde ([18F]FBA)9 for reaction
with free amines at the N-terminus or lysine residues of peptides,
and maleimides such as 4-[18F]fluorobenzaldehyde-O-(2-[2-[2-
maleimido-N-ethoxy]-ethoxy]-ethyl)oxime ([18F]FBOM)10 for reac-
tion with thiols on cysteine residues. A current challenge is to
find aqueous based methods of covalently modifying peptidic
ligands with [18F]fluoride to avoid azeotrope drying, such that
biomolecules can be rendered readily soluble and be labelled in
a reaction in the aqueous phase. The challenge, however, is that
fluoride is a very poor nucleophile in water and is diﬃcult to
secure. Some good aqueous based methods have been developed
recently such as the [18F]AlF methodology11 where [18F]fluoride
is secured by an aluminium-heterocycle complex tethered to a
relevant peptide.12
Scheme 1 (A) Native fluorinase-catalysed reaction to give FDA 2 as the
first step in fluorometabolite biosynthesis. (B) Fluorinase-catalysed trans-
halogenation reactions showing SeSAM intermediates, with modified C-2
acetylene-bearing substrates.
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The fluorinase enzyme functions best in buﬀer (pH 7.8, 37 1C)
under ambient conditions and may present some additional
advantages over current methods for this reason. We have
recently demonstrated that the C-2 position of the substrate
can be substituted with acetylene and this modified substrate,
2-ethynyl-ClDA (ClDEA, 6), is processed to 2-ethynyl-FDA (FDEA,
8) (B60% rate compared to ClDA).13 This led to the demonstra-
tion of a ‘last step’ labelling protocol of a cRGD peptide by
extending a tetraethyleneglycol (TEG) chain from the acetylene
moiety at C-2 of ClDEA 6 to a cRGD motif to give ClDEA-TEG-
RGD 9, which allowed for the last step fluorinase enzyme based
transhalogenation and radiolabelling of this peptide construct with
fluorine-18 under ambient conditions (Scheme 1B), generating
[18F]-FDEA-TEG-RGD [18F]-11.
In this Communication we demonstrate a complementary
two step protocol, both under aqueous, ambient (pH 7.8, 37 1C)
conditions, for labelling a cRGD peptide. This involves the
transhalogenation of ClDEA (6) using [18F]fluoride to generate a
novel acetylene-bearing radiolabelled prosthetic group, [18F]FDEA
[18F]-8, and then coupling the acetylene moiety to an azide bearing
cRDG peptide using a copper catalysed ‘click’ protocol.
We set out to investigate the copper-mediated click reaction
under cold conditions, and explore the reaction of both synthetic
FDEA (8), and that produced by fluorinase transhalogenation
with an azide bearing RGD peptide 12. Firstly, the fluorinase
enzyme catalysed transhalogenation of ClDEA 6 (Fig. 1A) was
carried out under our previously reported conditions13 to give a
78 : 22 mixture of FDEA (8, tR = 8.5 min) and ClDEA (6, tR =
10.5 min) in 2 hours (Fig. 1B). After heat precipitation and
centrifugation to remove the enzyme, the supernatant containing
FDEA 8 (and residual ClDEA 6) was reacted with c(RGDfK[N3]) 12 in
the presence of sodium ascorbate and the CuSO4–TBTA complex
(TBTA = tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine)14 to
efficiently generate the triazole, FDEA-RGD (13, tR = 12.8 min),
in 70 minutes (Fig. 1C). The click reaction also proceeded
efficiently with synthetic ClDEA 6 and FDEA 8 on a preparative
scale, providing samples of the anticipated products, ClDEA-
RGD 14 and FDEA-RGD 13, for use as reference compounds for
the radiolabelling experiments.
The chloromethyl substrate, ClDEA 6, was then explored
in enzymatic radiolabelling experiments using [18F]fluoride.
Although the reactions progressed at modest conversion in the
enzyme assays using [19F]fluoride illustrated in Fig. 1, previous
experience has shown that fluorinase catalysed radiochemical
reactions proceed much faster than assays under cold conditions.
The cyclotron generates a solution of [18F]fluoride at picomolar
concentration, while the fluorinase enzyme is added to this
solution at 15–20 mg ml1, which is a micromolar concentration.
Therefore there is up to a 106 excess of enzyme over fluoride ion
concentration in solution. Under these conditions the enzyme is
not catalytic, but operates under single turnover conditions. The
success of radiochemical experiments lies in converting as much
[18F]fluoride to organic [18F]fluorine as possible and generally very
good radiochemical conversions are achieved by fluorinase cata-
lysis with SAM substrates, because of the excess of the enzyme.
In the event [18F]FDEA [18F]-8 was produced in 69% radiochemi-
cal conversion (RCC). Fig. 2A shows the radiochemical HPLC trace of
fluorinase catalysed transhalogenation showing [18F]-8 (tR = 7.2 min)
as the only radiolabelled product, besides residual [18F]fluoride,
Fig. 1 (A) Fluorinase-catalysed transhalogenation (pH 7.8, 37 1C) of ClDEA
(yellow, 6) at t = 0 min. (B) Fluorinase-catalysed transhalogenation of ClDEA
(yellow, 6) to FDEA (green, 8) at t = 120min. (C) Click reaction of enzymatically
produced FDEA (8, green) with azido-RGD peptide 12 after 70 min showing a
new triazole product, FDEA-RGD (13, dark blue). ClDEA-RGD (red) is also
observed, from residual ClDEA 6 present after transhalogenation.
Fig. 2 (A) Radio-HPLC trace of fluorinase catalysed transhalogenation
with [18F]fluoride, producing [18F]FDEA [18F]-8. (B) UV-HPLC trace (254 nm)
of enzymatically produced [18F]FDEA [18F]-8 spiked with a synthetic
sample of [19F]FDEA 8. (C) Radio-HPLC trace of purified [18F]FDEA-RGD
[18F]-13. (D) UV-HPLC trace (254 nm) of purified [18F]FDEA-RGD [18F]-13
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illustrating the high chemoselectivity of the enzymatic radio-
fluorination. Spiking with a cold sample of [19F]FDEA 8 con-
firmed the identity of the radiolabelled product (Fig. 2B).
The click reaction of [18F]FDEA [18F]-8 with azido-RGD pep-
tide (12) was found to be complete within 30 minutes generating
[18F]FDEA-RGD ([18F]-13, tR = 8.7 min) quantitatively. [
18F]-13 was
then purified by reverse phase semi-preparative HPLC and
reformulated into 10% ethanol in saline to give a dose suitable
for an animal study (Fig. 2C). Total synthesis time was 2 hours
and produced [18F]FDEA in up to 20% non-decay corrected
radiochemical yield. Spiking with a cold sample of [19F]FDEA-
RGD confirmed the identity of the new product (Fig. 2D).
There is some uncertainty as to the metabolic stability of these
C-2 substituted adenosine analogues. If such compounds are
metabolised, such that fluoride ion is released, then they become
redundant as PET radiotracers because the released [18F]fluoride
accumulates in the bone.15 This issue was addressed satisfactorily
in the last step labelling study reported recently,13 where the
radiolabelled product was injected into healthy rats to evaluate
defluorination and bone uptake. The radiolabelled product in that
study, [18F]FDEA-TEG-RGD, [18F]-11 (Scheme 1B), proved to be
metabolically stable to [18F]fluoride release showing no enhanced
bone uptake, and normal urinary clearance.
We have carried out a similar study for [18F]-13 by injecting
two male Sprague-Dawley rats with a radiotracer. One rat was
imaged by PET-CT, and blood samples from both rats were
monitored to assess the metabolism of [18F]-13. The summed
PET-CT of the imaged rat showed negligible uptake of activity
in bone. Acetonitrile extracts of blood plasma samples taken at
various intervals (5, 15, 30 and 60 minutes post injection) from
both rats all showed a single radioactive compound present
in the reconstructed HPLC-radiochromatogram and negligible
[18F]fluoride ion release. This was confirmed to be [18F]-13 by
co-injection with [19F]-13, showing the stability of the construct
to metabolic processing.
The biodistribution of [18F]-13 in the PET-CT images was
similar to the natural biodistribution of aVb3, locating primarily
in the liver and intestinal wall, as well as the kidneys and
bladder (see Fig. 3 and Fig. S19, ESI†).16
Evaluating the binding of test molecules to immobilised aVb3
integrin is a standard method of assessing binding aﬃnities of
RGD peptides.17 The aﬃnity of the peptide for aVb3 is measured as
IC50, but normalized to the IC50 of a reference peptide (GRGDSPK)
to allow inter-assay comparisons. The normalized aﬃnity, ‘‘Q’’,
is defined as IC50(peptide)/IC50(GRGDSPK) by Haubner et al.
17
Aﬃnity of RGD, GRGDSPK, c(RGDfK[N3]) 12, and FDEA-RGD 8
for immobilised aVb3 integrin was measured against c(RGDfK[PEG-
PEG-biotin]) in a competition-based assay. The IC50 value of 8
was found to be 0.33 0.03 mM with a Q factor of 0.155
(Table 1). FDEA-RGD 8 retains the well-documented18 order of
magnitude with greater aﬃnity for aVb3 integrin compared to
the linear reference peptides in this assay e.g. RGD at 8.56 
2.24 mM/Q = 4.02. The IC50 was the same order of magnitude
as unmodified c(RGDfK[N3]) 12, which had an IC50 of 0.09 
0.005 mM. The Q factor for FDEA-RGD 8 compares moderately
well to other well-characterised high aﬃnity aVb3 ligands, such
as c(RGDfV) whose Q factor has been reported to be 0.033.19 These
data show that the fluorodeoxyadenosine moiety does not signifi-
cantly perturb the binding of the cRGD motif to aVb3 integrin.
In conclusion, we demonstrate a straightforward two-
step radiolabelling protocol for cRGD peptides. This method
complements our recently disclosed ‘last step’ radiolabelling
protocol and despite the extra step, it has some advantage in
that the enzyme substrate, ClDEA 6, is more readily prepared
synthetically. Normally fluorine-18 labelling protocols require
Fig. 3 (A) Sagittal and coronal summed PET-CT images (0–70 min) with
the head and thorax in the field of view (FOV) showing the accumulation of
[18F]-13 in the liver. The CT image in the grayscale, PET in colour. PET
images are presented as standard uptake values (SUV = {(tissue activity/mL)/
(injected activity/animal weight[g])}). Tracer uptake in the bone is negligible,
indicating that the construct is stable to defluorination. (B) Reconstructed
radio-HPLC chromatogram of acetonitrile extracts of plasma after 60 min
showed only [18F]FDEA-RGD [18F]-13 present in the plasma.
Table 1 IC50 values of RGD-containing peptide motifs measured as the
ability of the peptide to compete with c(RGDfK[PEG-PEG-biotin]) for
binding to immobilized aVb3 integrin. RGD and GRGDSPK are used as
reference peptides. Results are the average  standard error (s.e.) from
three independent experiments performed in triplicate. Q is the normal-
ised activity of the peptides, referenced to GRGDSPK
Compound IC50  s.e/mM Q
RGDa 8.56  2.24 4.019
GRGDSPK (Ref. peptide)a 2.13  0.41 1.000
c(RGDfK[N3]) 12 0.09  0.005 0.042
FDEA-RGD 13 0.33  0.03 0.155
a The IC50 values for these compounds were reported previously,
19 and
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[18F]-fluoride in dry, non-aqueous solvent. This method takes
place in aqueous buﬀer (pH 7.8) at 37 1C. The optimal ligands
for tumour imaging have to await the outcomes of in vivo
studies in diﬀerent animal tumour models.
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